Oculis (NASDAQ:OCS) Posts Quarterly Earnings Results, Beats Estimates By $0.10 EPS

Oculis (NASDAQ:OCS) posted its quarterly earnings results on Tuesday. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.10, Zacks reports. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.26 million. Oculis had a negative net margin of 8,613.92% and a negative return on equity of 39.31%.

Oculis Trading Down 4.6%

NASDAQ OCS opened at $7.28 on Thursday. Oculis has a 52 week low of $6.80 and a 52 week high of $34.47. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.35 and a current ratio of 8.35. The stock’s 50 day moving average price is $9.42 and its two-hundred day moving average price is $18.54. The stock has a market capitalization of $422.09 million, a price-to-earnings ratio of -4.26 and a beta of 0.67.

Analysts Set New Price Targets

Several research firms have issued reports on OCS. Wall Street Zen upgraded Oculis from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. HC Wainwright restated a “buy” rating and issued a $39.00 target price on shares of Oculis in a report on Wednesday, October 21st. Guggenheim decreased their price target on shares of Oculis to $40.00 and set a “buy” rating for the company in a report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oculis in a research report on Thursday, October 15th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Oculis from $23.00 to $20.00 and set an “overweight” rating for the company in a research note on Friday, August 14th. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $38.89.

About Oculis

Oculis is a global biopharmaceutical company focused on developing innovative treatments for eye diseases. The company’s research is centered on therapies that can be administered directly to the eye, including topical ophthalmic formulations and other approaches designed to improve drug delivery, efficacy, and patient convenience.

Oculis has developed a pipeline addressing ophthalmic conditions such as retinal diseases, diabetic macular edema, dry eye disease, and other disorders that can impair vision.